MYD88 and primary central nervous system lymphoma: Two previous studies involving a large number of PCNSL patients reported mutations in CD79B (83%) and MYD88 (79%) in 71 patients, and mutations in CD79B (41%) and MYD88 (58%) in 177 patients, respectively (69, 70).